JP2001503019A - 鳥類用ポリヌクレオチドワクチン製剤 - Google Patents

鳥類用ポリヌクレオチドワクチン製剤

Info

Publication number
JP2001503019A
JP2001503019A JP10506638A JP50663898A JP2001503019A JP 2001503019 A JP2001503019 A JP 2001503019A JP 10506638 A JP10506638 A JP 10506638A JP 50663898 A JP50663898 A JP 50663898A JP 2001503019 A JP2001503019 A JP 2001503019A
Authority
JP
Japan
Prior art keywords
virus
vaccine
plasmid
antigen
infectious
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10506638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503019A5 (enExample
Inventor
オードネ，ジャン―クリストフ
ブシャルドン，アナベル
リヴィエール，ミシェル
Original Assignee
メリアル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メリアル filed Critical メリアル
Publication of JP2001503019A publication Critical patent/JP2001503019A/ja
Publication of JP2001503019A5 publication Critical patent/JP2001503019A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/22011—Dicistroviridae
    • C12N2770/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP10506638A 1996-07-19 1997-07-16 鳥類用ポリヌクレオチドワクチン製剤 Pending JP2001503019A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR96/09339 1996-07-19
FR9609339A FR2751225B1 (fr) 1996-07-19 1996-07-19 Formule de vaccin polynucleotidique aviaire
PCT/FR1997/001326 WO1998003659A1 (fr) 1996-07-19 1997-07-16 Formule de vaccin polynucleotidique aviaire

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008282541A Division JP2009149608A (ja) 1996-07-19 2008-10-31 鳥類用ポリヌクレオチドワクチン製剤

Publications (2)

Publication Number Publication Date
JP2001503019A true JP2001503019A (ja) 2001-03-06
JP2001503019A5 JP2001503019A5 (enExample) 2005-03-10

Family

ID=9494451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP10506638A Pending JP2001503019A (ja) 1996-07-19 1997-07-16 鳥類用ポリヌクレオチドワクチン製剤
JP2008282541A Pending JP2009149608A (ja) 1996-07-19 2008-10-31 鳥類用ポリヌクレオチドワクチン製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008282541A Pending JP2009149608A (ja) 1996-07-19 2008-10-31 鳥類用ポリヌクレオチドワクチン製剤

Country Status (19)

Country Link
US (3) US6221362B1 (enExample)
EP (2) EP0914442B1 (enExample)
JP (2) JP2001503019A (enExample)
KR (1) KR20000065258A (enExample)
CN (2) CN1701788A (enExample)
AR (1) AR013063A1 (enExample)
AU (1) AU735184B2 (enExample)
BR (1) BR9710495A (enExample)
CA (1) CA2261343A1 (enExample)
CO (1) CO4700304A1 (enExample)
DE (1) DE69730839T2 (enExample)
ES (1) ES2232876T3 (enExample)
FR (1) FR2751225B1 (enExample)
HU (1) HU224830B1 (enExample)
ID (1) ID19475A (enExample)
MA (1) MA24268A1 (enExample)
NZ (1) NZ333779A (enExample)
TN (1) TNSN97120A1 (enExample)
WO (1) WO1998003659A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524192A (ja) * 2003-05-06 2006-10-26 シュヴァイツァー ケミカル コーポレーション リミティッド 禽用ワクチンの効能を改善できるワクチン増強因子（ｖａｆ）

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
ZA978434B (en) * 1996-09-27 1998-03-26 Akzo Nobel Nv Inactivated vaccines.
US6468984B1 (en) * 1999-06-08 2002-10-22 Innovo Biotechnologies Ltd. DNA vaccine for protecting an avian against infectious bursal disease virus
AU4606000A (en) * 1999-06-10 2001-01-02 Agricultural Research Council Vaccine for newcastle disease virus
AR031405A1 (es) * 2000-11-21 2003-09-24 Wyeth Corp Metodos y vacunas para conferir proteccion in ovo contra la rinotraqueitis del pavo
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
IL145397A0 (en) * 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
US7615209B2 (en) 2001-09-12 2009-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions of NDV and methods of use thereof for treatment of cancer
US7029681B2 (en) * 2002-03-08 2006-04-18 Schweitzer Chemical Corporation Multiple and multivalent DNA vaccines in ovo
EP1980268A2 (en) * 2002-04-12 2008-10-15 Ilaria Capua Vaccination methods against avian influenza virus
MXPA05003850A (es) 2002-10-15 2005-06-22 Wyeth Corp Metodos de ensayo para la deteccion de un virus en una muestra de tejido aviar.
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
ATE510928T1 (de) 2004-02-19 2011-06-15 Univ Alberta Leptinpromotor-polymorphismen und verwendungen davon
HRP20100314T1 (hr) 2005-04-25 2010-08-31 Merial Ltd. Cjepivo protiv nipah virusa
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
DE102005040812A1 (de) * 2005-08-27 2007-03-15 Few Fahrzeugelektrikwerk Gmbh & Co. Kg Elektrischer Anschluss sowie Verfahren zu dessen Verbindung mit der Scheibe eines Kraftfahrzeugs
US7598364B2 (en) 2005-11-14 2009-10-06 Merial Limited Plasmid encoding canine BMP-7
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US20080274137A1 (en) * 2007-05-02 2008-11-06 Jean Christophe Francis Audonnet DNA plasmids having improved expression and stability
KR101445903B1 (ko) 2007-05-02 2014-09-29 메리얼 리미티드 향상된 발현 및 안정성을 갖는 ｄｎａ 플라스미드
TW201004864A (en) * 2008-06-03 2010-02-01 Asahi Glass Co Ltd Method for producing core-shell particle, core-shell particle, method for producing hollow particle, paint composition and article
EP3542815A1 (en) 2008-11-28 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Recombinant avian influenza vaccine and uses thereof
CN102428099B (zh) 2009-04-03 2016-03-16 梅里亚有限公司 运载新城疫病毒的禽疫苗
US10633667B2 (en) 2009-12-28 2020-04-28 Boehringer Ingelheim Animal Health USA Inc. Recombinant NDV antigen and uses thereof
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
CA2792118C (en) 2010-03-12 2022-07-12 Merial Limited Bluetongue virus recombinant vaccines and uses thereof
MX344103B (es) 2010-08-31 2016-12-05 Merial Ltd Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
EP2694678A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment
EP2694677A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
KR102007444B1 (ko) 2011-04-25 2019-08-06 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물
WO2012166450A1 (en) 2011-05-27 2012-12-06 Merial Limited Genetic vaccines against hendra virus and nipah virus
US9669085B2 (en) 2011-06-01 2017-06-06 Merial Inc. Needle-free administration of PRRSV vaccines
SI2741740T1 (sl) 2011-08-12 2017-08-31 Merial, Inc. Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv
WO2013082327A1 (en) * 2011-11-30 2013-06-06 Merial Limited Recombinant hvt vectors expressing antigens of avian pathogens and uses thereof
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
JP6260972B2 (ja) 2012-02-14 2018-01-17 メリアル インコーポレイテッド 狂犬病タンパク質及びｏｘ４０タンパク質の両方を発現する組換えポックスウイルスベクター並びに前記ベクターから製造されるワクチン
CA2864106C (en) 2012-02-14 2017-10-17 Merial Limited Rotavirus subunit vaccines and methods of making and use thereof
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
EP2861248B1 (en) 2012-06-13 2017-11-15 Merial, Inc. Reassortant btv and ahsv vaccines
CN102719567A (zh) * 2012-07-05 2012-10-10 广东温氏食品集团有限公司 禽传染性支气管炎病毒h120毒株的pcr检测引物及检测方法
HK1216006A1 (zh) 2013-03-12 2016-10-07 Boehringer Ingelheim Animal Health USA Inc. 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
ES2690836T3 (es) 2014-05-19 2018-11-22 Merial, Inc. Dispositivo para la inyección in ovo condicional
IL241841B (en) * 2014-09-30 2019-09-26 Univ Free State Production of proteins for human and animal health using yarrowia lipolytica
CA2966191A1 (en) 2014-11-03 2016-05-12 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
CN104881148B (zh) * 2015-05-15 2017-12-15 苏州达方电子有限公司 键盘及其控制方法
AR105482A1 (es) 2015-06-23 2017-10-11 Merial Inc Vectores virales recombinantes que contienen la proteína menor del virus del síndrome reproductor y respiratorio porcino (prrsv) y sus métodos de elaboración y uso
MA42653A (fr) 2015-08-20 2018-06-27 Merial Inc Vaccins recombinants contre le fcv et utilisations de ceux-ci
MA43016A (fr) 2015-09-29 2018-08-08 Merial Inc Vaccins à particules pseudo-virales (vlp) de parvovirus canin (cpv) et utilisations associées
NZ743236A (en) 2015-11-23 2019-12-20 Boehringer Ingelheim Animal Health Usa Inc Fmdv and e2 fusion proteins and uses thereof
TWI760322B (zh) 2016-01-29 2022-04-11 美商百靈佳殷格翰動物保健美國有限公司 重組腺病毒載體裝載之fmdv疫苗及其用途
CN107099513B (zh) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
EP3766514A4 (en) * 2018-01-26 2022-03-02 National Federation of Agricultural Cooperative Associations Antigen-surface-coupled liposome vaccine for non-human animals
CN110777122A (zh) * 2019-10-21 2020-02-11 青岛易邦生物工程有限公司 一种表达ibdv的vp2蛋白的重组ⅰ型马立克氏病病毒
CN115089700B (zh) * 2022-05-25 2025-07-25 永州中古生物技术有限公司 一种抗β属冠状病毒的疫苗组合物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0474676A4 (en) * 1989-05-30 1993-02-24 The Commonwealth Scientific And Industrial Research Organization Production of ibdv vp2 in highly immunogenic form
JPH06509235A (ja) * 1991-07-26 1994-10-20 ヴァイロジェネティクス　コーポレイション 伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン
FR2697534A1 (fr) * 1992-11-02 1994-05-06 Rhone Merieux Virus herpès de la dinde recombinant pour la réalisation de vaccin de la maladie de Gumboro, son procédé de préparation et vaccin obtenu.
EP0620277A1 (en) * 1993-03-18 1994-10-19 Merck & Co. Inc. Nucleic acid pharmaceuticals
JP3606870B2 (ja) * 1993-04-14 2005-01-05 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション 組換えトリアデノウイルスベクター
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
JPH08116976A (ja) * 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
WO1996021034A1 (fr) * 1994-12-30 1996-07-11 Rhone Merieux Vaccin vivant recombinant aviaire
FR2728794B1 (fr) * 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
US5916879A (en) 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
US6468984B1 (en) * 1999-06-08 2002-10-22 Innovo Biotechnologies Ltd. DNA vaccine for protecting an avian against infectious bursal disease virus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006524192A (ja) * 2003-05-06 2006-10-26 シュヴァイツァー ケミカル コーポレーション リミティッド 禽用ワクチンの効能を改善できるワクチン増強因子（ｖａｆ）

Also Published As

Publication number Publication date
WO1998003659A1 (fr) 1998-01-29
TNSN97120A1 (fr) 2005-03-15
EP0914442B1 (fr) 2004-09-22
ID19475A (id) 1998-07-16
US6221362B1 (en) 2001-04-24
AR013063A1 (es) 2000-12-13
AU735184B2 (en) 2001-07-05
US6464984B2 (en) 2002-10-15
CA2261343A1 (fr) 1998-01-29
DE69730839D1 (de) 2004-10-28
HUP9902790A2 (hu) 1999-12-28
US20030124145A1 (en) 2003-07-03
AU3773697A (en) 1998-02-10
CO4700304A1 (es) 1998-12-29
US20020037292A1 (en) 2002-03-28
HUP9902790A3 (en) 2000-03-28
FR2751225B1 (fr) 1998-11-27
CN1225685A (zh) 1999-08-11
NZ333779A (en) 2000-07-28
HU224830B1 (en) 2006-02-28
FR2751225A1 (fr) 1998-01-23
JP2009149608A (ja) 2009-07-09
DE69730839T2 (de) 2005-09-29
BR9710495A (pt) 1999-08-17
EP1523992A1 (fr) 2005-04-20
KR20000065258A (ko) 2000-11-06
MA24268A1 (fr) 1998-04-01
CN1701788A (zh) 2005-11-30
EP0914442A1 (fr) 1999-05-12
ES2232876T3 (es) 2005-06-01

Similar Documents

Publication Publication Date Title
JP2001503019A (ja) 鳥類用ポリヌクレオチドワクチン製剤
US7534559B2 (en) Feline polynucleotide vaccine formula
RU2319504C2 (ru) Вакцина собак против бешенства (варианты), способ вакцинации (варианты), набор для вакцинации (варианты)
CA2660355C (en) Polynucleotide vaccine formulation against pathologies of the horse
JP2000516200A (ja) ウシの呼吸病に対するポリヌクレオチドワクチン処方
ES2283105T3 (es) Vacunas en el adn con polimeros de acido acrilico o metacrilico o de ema (r) para los caballos.
JP2003502345A (ja) ペットまたはスポ−ツ用動物のためのｄｎａワクチン
AU2004210602B2 (en) Avian polynucleotide vaccine formula
AU777623B2 (en) Avian polynucleotide vaccine formula
AU773266B2 (en) Feline polynucleotide vaccine formula
AU2007202367A1 (en) Avian polynucleotide vaccine formula
AU2004205140B2 (en) Feline polynucleotide vaccine formula
AU2008203549A1 (en) Feline polynucleotide vaccine formula
NZ506427A (en) A canidae vaccine comprising the rabies G gene under the control of the CMV-IE promoter

Legal Events

Date Code Title Description
A72 Notification of change in name of applicant

Free format text: JAPANESE INTERMEDIATE CODE: A721

Effective date: 20040623

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20040623

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20040623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071101

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071210

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080109

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080214

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080708